[Skip to Content]

NHS England reverses decision on use of adalimumab for children with uveitis

11 November 2015

The Royal College of Ophthalmologists is delighted to learn that submission of further evidence and negotiation on the use of adalimumab has been approved by NHS England for use in children with uveitis that threatens their sight, and for whom other treatments have proven ineffective. The Clinical Reference Group for specialised ophthalmology services (CRG), under the leadership of Alison Davis with particular input from Michael Clarke, Clive Edlesten and Professor A. V. Ramanan,  Consultant Paediatric Rheumatologist, has worked hard to achieve this specialised commissioning which will offer treatment for children who otherwise would be at risk of visual loss.

This has not been an easy process, but it is excellent news and reflects a dogged determination on behalf of patients by the CRG and other patient groups and organisations.

To review the updated policy document that outlines the arrangements for funding of uveitis treatment for the population in England, please visit the NHS England website.

https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/11/d12x02-paediatric-uveitis-anti-tnf.pdf

https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/11/adalimumab-pat-info-leaflet.pdf